BeiGene
BGNE
$148.85
Share price
-3.50%
Change (1 day)
-33.39%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Net assets
Net assets on the balance sheet as of March 2024 : $3.36 B
According to BeiGene
's latest financial reports the company has $3.36 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
BeiGene - Net assets on balance sheet (from 2014 to 2024)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2023-12-31 | $3.53 B | -19.3% |
| 2022-12-31 | $4.38 B | -28.52% |
| 2021-12-31 | $6.13 B | 58.5% |
| 2020-12-31 | $3.86 B | 295.48% |
| 2019-12-31 | $0.97 B | -44.21% |
| 2018-12-31 | $1.75 B | 156.29% |
| 2017-12-31 | $0.68 B | 93.88% |
| 2016-12-31 | $0.35 B | 374.85% |
| 2015-12-31 | $74.31 M | 188.42% |
| 2014-12-31 | $25.76 M | -166.54% |
| 2013-12-31 | $-38.73 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $1.25 B | -62.72% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $6.01 M | -99.82% | 🇺🇸 USA |